BioNotebook: Deals from Five Prime/GSK, Actavis/Rhythm, Apricus/Forendo; a DARPA collaboration and IPO news
This article was originally published in Scrip
Executive Summary
Five Prime, GSK expand collaboration; Actavis gains option to buy Rhythm subsidiary; Apricus licenses fispemifene from Forendo; Inovio, MedImmune partner with DARPA money; and IPO updates from DBV, Coherus, S1 Biopharma and Tobira.
You may also be interested in...
Forendo Pharma: Tackling The Endometriosis Challenge
Emerging Company Profile: Finland's Forendo Pharma hopes an imminent improvement in diagnostic possibilities will eventually help it commercialize a drug for endometriosis, which it believes could enable more effective treatment of a disease that afflicts large numbers of women.
‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.